Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma

Cancer Letters

Volumn 307, Issue 1, 2011, Pages 93-103

  Chen, Wei ^a,b   Wu, Yuqiang ^a   Liu, Wei ^b   Wang, Guoying ^a   Wang, Xiaoyun ^a   Yang, Yang ^a   Chen, Wenjie ^b   Tai, Yan ^b   Lu, Minqiang ^a   Qian, Qijun ^c   Zhang, Qi ^a,b   Chen, Guihua ^a,b  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Provincial Key Laboratory of Liver Disease Research   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Fiber chimeric oncolytic adenoviruses; Gene viral therapy; Hepatocellular carcinoma; P53 gene

Indexed keywords

ANTINEOPLASTIC AGENT; MEMBRANE COFACTOR PROTEIN; ONCOLYTIC ADENOVIRUS; PROTEIN P53; SG600; SG600 P53; SG635; SG635 P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL DIVISION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; EMBRYO; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD46; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA;

EID: 79957471892     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.021     Document Type: Article

References (35)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
2. Llovet J.M. Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol. 2005, 40:225-235.
3. Mathis J.M., Stoff-Khalili M.A., Curiel D.T. Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene 2005, 24:7775-7791.
4. Toth K., Dhar D., Wold W.S. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin. Biol. Ther. 2010, 10:353-368.
5. Yamamoto M., Curiel D.T. Current issues and future directions of oncolytic adenoviruses. Mol. Ther. 2010, 18:243-250.
6. Guse K., Hemminki A. Cancer gene therapy with oncolytic adenoviruses. J. BUON 2009, 14(Suppl. 1):S7-15.
7. Wang X., Su C., Cao H., Li K., Chen J., Jiang L., Zhang Q., Wu X., Jia X., Liu Y., Wang W., Liu X., Wu M., Qian Q. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol. Cancer Ther. 2008, 7:1598-1603.
8. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., Horwitz M.S., Crowell R.L., Finberg R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1320-1323.
9. Tomko R.P., Xu R., Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl Acad. Sci. USA 1997, 94:3352-3356.
10. Kim M., Zinn K.R., Barnett B.G., Sumerel L.A., Krasnykh V., Curiel D.T., Douglas J.T. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur. J. Cancer 2002, 38:1917-1926.
11. Matsumoto K., Shariat S.F., Ayala G.E., Rauen K.A., Lerner S.P. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 2005, 66:441-446.
12. Yamamoto H., Itoh F., Sakamoto H., Nakajima Y., Une Y., Hinoda Y., Imai K. Association of reduced cell adhesion regulator messenger RNA expression with tumor progression in human hepatocellular carcinoma. Int. J. Cancer 1997, 74:251-254.
13. Gaggar A., Shayakhmetov D.M., Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 2003, 9:1408-1412.
14. Hara T., Kojima A., Fukuda H., Masaoka T., Fukumori Y., Matsumoto M., Seya T. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Brit J Haematol 1992, 82:368-373.
15. Kinugasa N., Higashi T., Nouso K., Nakatsukasa H., Kobayashi Y., Ishizaki M., Toshikuni N., Yoshida K., Uematsu S., Tsuji T. Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Brit. J. Cancer 1999, 80:1820-1825.
16. Murray K.P., Mathure S., Kaul R., Khan S., Carson L.F., Twiggs L.B., Martens M.G., Kaul A. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol. Oncol. 2000, 76:176-182.
17. Thorsteinsson L., O'Dowd G.M., Harrington P.M., Johnson P.M. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS 1998, 106:869-878.
18. Vaha-Koskela M.J., Heikkila J.E., Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Lett. 2007, 254:178-216.
19. Reddy P.S., Ganesh S., Yu D.C. Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin. Cancer Res. 2006, 12:2869-2878.
20. Hoffmann D., Meyer B., Wildner O. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. J. Gene Med. 2007, 9:764-778.
21. Wohlfahrt M.E., Beard B.C., Lieber A., Kiem H.P. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res. 2007, 67:8783-8790.
22. Ganesh S., Gonzalez Edick M., Idamakanti N., Abramova M., Vanroey M., Robinson M., Yun C.O., Jooss K. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 2007, 67:4399-4407.
23. Wang G., Li G., Liu H., Yang C., Yang X., Jin J., Liu X., Qian Q., Qian W. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J. Gene Med. 2009, 11:477-485.
24. Zhang Q., Chen G., Peng L., Wang X., Yang Y., Liu C., Shi W., Su C., Wu H., Liu X., Wu M., Qian Q. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin. Cancer Res. 2006, 12:6523-6531.
25. Onimaru M., Ohuchida K., Nagai E., Mizumoto K., Egami T., Cui L., Sato N., Uchino J., Takayama K., Hashizume M., Tanaka M. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. Cancer Lett. 2010, 294:178-186.
26. Rein D.T., Breidenbach M., Kirby T.O., Han T., Siegal G.P., Bauerschmitz G.J., Wang M., Nettelbeck D.M., Tsuruta Y., Yamamoto M., Dall P., Hemminki A., Curiel D.T. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin. Cancer Res. 2005, 11:1327-1335.
27. Kawakami Y., Li H., Lam J.T., Krasnykh V., Curiel D.T., Blackwell J.L. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res. 2003, 63:1262-1269.
28. Miyazawa N., Crystal R.G., Leopold P.L. Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J. Virol. 2001, 75:1387-1400.
29. Miyazawa N., Leopold P.L., Hackett N.R., Ferris B., Worgall S., Falck-Pedersen E., Crystal R.G. Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J. Virol. 1999, 73:6056-6065.
30. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127:1323-1334.
31. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 2005, 16:1016-1027.
32. Kim K.H., Ryan M.J., Estep J.E., Miniard B.M., Rudge T.L., Peggins J.O., Broadt T.L., Wang M., Preuss M., Siegal G.P., Hemminki A., Harris R.D., Aurigemma R., Curiel D., Alvarez R.D. A new generation of serotype chimeric infectivity-enhanced CRAds: the safety profile of Ad5/3-Delta24 in advance of a phase I clinical trial in ovarian cancer patients. Hum. Gene Ther. 2010.
33. Bernt K.M., Ni S., Gaggar A., Li Z.Y., Shayakhmetov D.M., Lieber A. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol. Ther. 2003, 8:746-755.
34. Sova P., Ren X.W., Ni S., Bernt K.M., Mi J., Kiviat N., Lieber A. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. 2004, 9:496-509.
35. Tsujimura A., Shida K., Kitamura M., Nomura M., Takeda J., Tanaka H., Matsumoto M., Matsumiya K., Okuyama A., Nishimune Y., Okabe M., Seya T. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem. J. 1998, 330(Pt 1):163-168.